{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:02:17Z","timestamp":1789164137263,"version":"build-2803163510"},"reference-count":30,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2022.2524","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T09:37:59Z","timestamp":1645695479000},"source":"Crossref","is-referenced-by-count":15,"title":["Cancer cachexia as a determinant of efficacy of first\u2011line pembrolizumab in patients with advanced non\u2011small cell lung cancer"],"prefix":"10.3892","volume":"16","author":[{"given":"Hironori","family":"Fujii","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizo","family":"Kaito","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Kinomura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Yanase","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenobu","family":"Gomyo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawae","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masachika","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu University Graduate School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"key20220330115636_b1-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20220330115636_b2-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20220330115636_b3-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20220330115636_b4-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase \u2162 study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20220330115636_b5-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"key20220330115636_b6-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"key20220330115636_b7-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF (V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20220330115636_b8-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"9004","key":"key20220330115636_b9-MCO-16-4-02524","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib (INC280) in MET\u0394ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase \u2161 GEOMETRY mono-1 study","volume":"37 (Suppl 15)","author":"Wolf","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20220330115636_b10-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key20220330115636_b11-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key20220330115636_b12-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"key20220330115636_b13-MCO-16-4-02524"},{"issue":"119","key":"key20220330115636_b14-MCO-16-4-02524","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"key20220330115636_b15-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","article-title":"Predictive value of PD-L1 diagnostics","volume":"39","author":"Schildhaus","year":"2018","journal-title":"Pathologe"},{"key":"key20220330115636_b16-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_289967","article-title":"Beyond tumor PD-L1: Beyond tumor PD-L1: Emerging genomic biomarkers for checkpoint inhibitor immunotherapy","volume":"40","author":"Lagos","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20220330115636_b17-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.7314\/apjcp.2015.16.18.8075","article-title":"Sarcopenia in cancer patients","volume":"16","author":"Chindaprasirt","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20220330115636_b18-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20220330115636_b19-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia-sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"issue":"450","key":"key20220330115636_b20-MCO-16-4-02524","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040450","article-title":"Association of sarcopenia with and efficacy of anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer","volume":"8","author":"Nishioka","year":"2019","journal-title":"J Clin Med"},{"key":"key20220330115636_b21-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20220330115636_b22-MCO-16-4-02524"},{"issue":"2447","key":"key20220330115636_b23-MCO-16-4-02524","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"key":"key20220330115636_b24-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jcsm.12528","article-title":"Cancer cachexia and its pathophysiology: Links with sarcopenia, anorexia and asthenia","volume":"11","author":"Peixoto da Silva","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key20220330115636_b25-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2016.02.013","article-title":"Early weight loss during chemoradiotherapy has a detrimental impact on outcome in NSCLC","volume":"11","author":"Sanders","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20220330115636_b26-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","article-title":"Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?","volume":"90","author":"Ross","year":"2004","journal-title":"Br J Cancer"},{"key":"key20220330115636_b27-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1101\/gad.276733.115","article-title":"Mechanisms of metabolic dysfunction in cancer-associated cachexia","volume":"30","author":"Petruzzelli","year":"2016","journal-title":"Genes Dev"},{"key":"key20220330115636_b28-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"key":"key20220330115636_b29-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"key20220330115636_b30-MCO-16-4-02524","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:00:32Z","timestamp":1648630832000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2022.2524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2,24]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2022.2524","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"article-number":"91"}}